Isolagen, Inc. Reports Results of Shareholders Annual Meeting
November 05 2007 - 4:00PM
PR Newswire (US)
Dr. Kenneth A. Selzer Joins Company's Board of Directors EXTON,
Pa., Nov. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (AMEX:ILE)
today announced the results of its 2007 Annual Meeting of
Stockholders, held today in Exton, Pennsylvania. Stockholders
elected Dr. Kenneth A. Selzer to serve as a new Director. Dr.
Selzer has been a partner with the venture capital firm of
Finistere Ventures. Concurrently, since 2005, Dr. Selzer has been
executive director of the Hallowell-West Medical Center, which
specializes in the diagnosis and treatment of patients with
Attention Deficient Disorders (ADD/ADHD) and associated learning
disorders. From 2002 until 2005, Dr. Selzer was a general partner
with Neuropractice Consulting Group, which provides specialized
services for companies investing in drugs, biologics and medical
devices. Dr. Selzer is currently on the Board of Directors of INC
Research, a global clinical research organization (CRO) and a
company which he founded in 1996. Dr. Selzer is a graduate of both
the UCLA School of Medicine and the OPM executive management
program at Harvard Business School and is a Diplomat of both the
American Board of Neurology and the American Board of Pain
Medicine. "We are pleased to welcome Dr. Selzer to our Board of
Directors," said Nicholas L. Teti, Chairman and CEO of Isolagen
Inc. "Ken brings a wealth of clinical, medical and business
knowledge to Isolagen and we look forward to benefiting from his
broad experience." Stockholders also re-elected Steven Morrell,
Partner, Teknoinvest AS, and Marshall G. Webb, President of Polaris
Group, as Directors. The terms of these three Directors will run
through the 2010 Annual Meeting of Stockholders. Further, the
Company's stockholders ratified the appointment of BDO Seidman, LLP
as the Company's auditors for the year ending December 31, 2007.
About Isolagen, Inc. Isolagen(TM), Inc. (AMEX:ILE) is an aesthetic
and therapeutic company committed to developing and commercializing
scientific advances and innovative technologies. The company's
technology platform includes the Isolagen Process(TM), a cell
processing system for skin and tissue rejuvenation which is
currently in clinical development for a broad range of aesthetic
and therapeutic applications including wrinkles, acne scars, burns
and periodontal disease. Isolagen also commercializes a
scientifically-advanced line of skincare systems through its
majority-owned subsidiary, Agera(R) Laboratories, Inc. For
additional information, please visit http://www.isolagen.com/.
Isolagen Forward Looking Statements All statements in this news
release that are not based on historical fact are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. While management has
based any forward-looking statements contained herein on its
current expectations, the information on which such expectations
were based may change. These forward-looking statements rely on a
number of assumptions concerning future events and are subject to a
number of risks, uncertainties, and other factors, many of which
are outside of our control, that could cause actual results to
materially differ from such statements. Such risks, uncertainties,
and other factors include, but are not necessarily limited to,
those set forth under Item 1A "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2006, as
updated in "Item 1A. Risk Factors" in the Company's Quarterly
Reports on Form 10-Q. We operate in a highly competitive and
rapidly changing environment, thus new or unforeseen risks may
arise. Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results. We
disclaim any intention to, and undertake no obligation to, update
or revise any forward-looking statements. Readers are also urged to
carefully review and consider the other various disclosures in the
Company's Annual Report on Form 10-K for the year ended December
31, 2006, as well as other public filings with the SEC since such
date. DATASOURCE: Isolagen, Inc. CONTACT: Media, Mike Beyer, Sam
Brown Inc., +1-773-463-4211, , for Isolagen; Investors, Charles
Huiner, Isolagen, +1-484-713-6200, Web site:
http://www.isolagen.com/
Copyright
Isolagen (AMEX:ILE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Isolagen (AMEX:ILE)
Historical Stock Chart
From Jul 2023 to Jul 2024